Women's Health News

RSS

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

The National Cancer Institute has awarded Albert Einstein College of Medicine of Yeshiva University $4.1 million to test the microbicide Carraguard- against the human papillomavirus, which causes cervical cancer. The research will evaluate the efficacy of Carraguard- - a clear gel made from the seaweed derivative carrageenan - in preventing new HPV infections in women.

26 Jul 2010

Tarsa Therapeutics completes patient enrollment in Phase III ORACAL trial of oral calcitonin

Unigene Laboratories, Inc. today noted that Tarsa Therapeutics has completed patient enrollment in the Phase III ORACAL trial of Tarsa's oral calcitonin product for the treatment of postmenopausal osteoporosis. Unigene licensed the product to Tarsa and owns 26% of the company.

23 Jul 2010

GRB7 gene drives an aggressive form of breast cancer, researchers find

Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.

23 Jul 2010

GOP questions math of HHS' premium hike estimates; Abortion issue defining implementation

Senate Republican leaders are questioning an estimate by the Department of Health and Human Services that the effect of the new health law on insurance premiums will likely be less than 1 percent, The Hill reports.

23 Jul 2010

China Sky One Medical receives SFDA approval for producing Ciclopirox Olamine Vaginal Suppositories

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China, today announced that the Company has obtained approval from the State Food and Drug Administration in China for the production of Ciclopirox Olamine Vaginal Suppositories.

23 Jul 2010

Choice between late-term abortion or keeping an unhealthy foetus

Most pregnant women whose foetus is proven to have a genetic abnormality choose to have an abortion, but reaching that decision is a painful, exhausting process for most of them. "The women's doubt, pain and sorrow make abortion more moral - in the eyes of society as well as her own," says Sølvi Marie Risøy, a researcher at the Stein Rokkan Centre for Social Studies, University of Bergen.

23 Jul 2010

Health bodies to discuss steps to further reduce mother to child HIV transmission

Transmission of HIV to children before or at birth has dropped dramatically around the country in the last decade since the advent of powerful new therapies. That certainly is true for Florida, where each year, fewer than 10 babies are born with the disease despite the fact that more than 600 HIV-positive women each year, on average, give birth.

23 Jul 2010

Fla. doctors consider cutting ties to AMA; Indiana seeks to get more uninsured covered; LA continues to seek leader for troubled health department

The House of Delegates of the Florida Medical Association is scheduled to consider a resolution severing ties with the American Medical Association because of its support for the healthcare reform law. The Florida group will consider the move at its annual meeting next month. The scathing resolution takes the AMA to task for having 'failed to achieve one single concession' in the healthcare reform bill.

23 Jul 2010

Waiting times for abortions in New Zealand need to be reduced

Women in New Zealand wait an average of 25 days to get a termination of pregnancy, from the date of their first visit to the doctor. Researchers writing in BioMed Central's open access journal Reproductive Health studied the timeliness of services provided at nine New Zealand clinics, finding that efforts need to be made by clinics and referring doctors to reduce the waiting times.

23 Jul 2010

2010 Life Beyond Cancer Retreat invites applications

The Life Beyond Cancer Foundation is calling for applications from cancer survivors, oncology nurses, social workers, oncologists, and primary care physicians who help diagnose cancer to attend the 2010 Life Beyond Cancer Retreat. The 11th annual retreat, held Nov. 18 – 21 at Lakeway Resort & Spa in Austin, Texas, helps women rekindle their spirits, relax their minds and bodies, and rejuvenate their souls.

23 Jul 2010

African ancestry associated with triple-negative breast cancer: Study

A new study finds that African ancestry is linked to triple-negative breast cancer, a more aggressive type of cancer that has fewer treatment options.Researchers at the University of Michigan Comprehensive Cancer Center found that, among women with breast cancer, 82 percent of African women were triple negative, 26 percent of African-Americans were and 16 percent of white Americans were.

23 Jul 2010

Drugs can save African infants' lives

Researchers at the University of Sydney have found the combined intake of iron-folic acid supplements with World Health Organisation (WHO)-endorsed anti-malarial drugs during pregnancy could reduce early infant mortality in sub-Saharan Africa by a quarter.

22 Jul 2010

Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.

22 Jul 2010

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.

22 Jul 2010

Four areas that impact weight, obesity in women identified

The information gap and general lack of understanding of obesity's unique and disproportionate impact on women contributes to the challenges of the 65 million American women who are considered overweight or obese, said the Strategies to Overcome and Prevent (STOP) Obesity Alliance Task Force on Women at a meeting on Capitol Hill today.

22 Jul 2010

Repros granted IRB approval to commence low dose Proellex study

Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.

22 Jul 2010

Correlates of HIV stigma in HIV-positive women: Study

For some women, planning a family can be the first step towards one of life's most rewarding experiences. But a study led by Ryerson University researchers has found strong evidence that some HIV-positive women feel that they are being judged negatively by their healthcare providers for wanting to become moms and feel stigmatized by their physicians due to their medical condition.

22 Jul 2010

Women's Health News

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

Tarsa Therapeutics completes patient enrollment in Phase III ORACAL trial of oral calcitonin

GRB7 gene drives an aggressive form of breast cancer, researchers find

GOP questions math of HHS' premium hike estimates; Abortion issue defining implementation

China Sky One Medical receives SFDA approval for producing Ciclopirox Olamine Vaginal Suppositories

Choice between late-term abortion or keeping an unhealthy foetus

Health bodies to discuss steps to further reduce mother to child HIV transmission

Fla. doctors consider cutting ties to AMA; Indiana seeks to get more uninsured covered; LA continues to seek leader for troubled health department

Waiting times for abortions in New Zealand need to be reduced

2010 Life Beyond Cancer Retreat invites applications

African ancestry associated with triple-negative breast cancer: Study

Drugs can save African infants' lives

Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Four areas that impact weight, obesity in women identified

Repros granted IRB approval to commence low dose Proellex study

Correlates of HIV stigma in HIV-positive women: Study

Study reveals link between anti-TPO antibodies and placental abruption

Sec. of State Clinton addresses Afghan women's rights during visit to Kabul

Researchers receive $780,000 to study estrogen levels, behavior of breast cancer tumors

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News